Evogliptin/metformin - Dong-A ST

Drug Profile

Evogliptin/metformin - Dong-A ST

Alternative Names: DA-1229_01; Sugamet

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator Dong-A ST
  • Class Amides; Antihyperglycaemics; Biguanides; Fluorobenzenes; Piperazines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Type 2 diabetes mellitus

Most Recent Events

  • 05 Jan 2016 Registered for Type-2 diabetes mellitus in South Korea (PO)
  • 01 Jun 2015 Preregistration for Type-2 diabetes mellitus in South Korea (PO)
  • 27 Nov 2014 Dong-A ST completes a phase I trial in Healthy volunteers in South Korea (NCT02167061)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top